Tumor-on-chip’s alliance with molecular pathology against metastatic disease

Applying patient-derived bioprinted tumors and organs for clinical purpose and developing standardized 4D and 5D bioprinting protocols would allow assessment of cancer response to treatments in a dynamic and faithfully reconstructed microenvironment. Integration of advanced molecular diagnostics and multi-OMICS data, with customized small-scale tumor models, assisted by AI-powered tools, requires a multidisciplinary framework. This integrated approach can upgrade clinical management of metastatic diseases, by accelerating the identification of actionable biomarkers and resistance mechanisms for timely therapy adjustments, thus enabling tailored treatment regimens based on individual tumor behavior.